20
Aurobindo Pharma Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RIVASTIGMINE USP, with a corresponding US DMF Number 29519.
Remarkably, this DMF maintains an Active status since its submission on July 13, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 13, 2015, and payment made on July 10, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II